We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+14.54%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.47B
AUM Growth
-$118M
(-4.6%)
Cap. Flow
-$497M
Cap. Flow
% of AUM
-20.15%
Top 10 Holdings %
Top 10 Hldgs %
35.06%
Holding
147
New
13
Increased
26
Reduced
28
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$70.1M |
| 2 |
ADPT
Adeptus Health Inc
ADPT
|
+$48.6M |
| 3 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$22.8M |
| 4 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$17.2M |
| 5 |
XNPT
XENOPORT, INC.
XNPT
|
+$15.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLUE
bluebird bio
BLUE
|
+$41.3M |
| 2 |
NXTM
NxStage Medical Inc.
NXTM
|
+$32.2M |
| 3 |
ELGX
Endologix Inc
ELGX
|
+$28.8M |
| 4 |
GSK
GSK
|
+$24.8M |
| 5 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$22.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.33% |
| 2 | Financials | 4.33% |
| 3 | Technology | 0.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALPN
26
DELISTED
Alpine Immune Sciences Inc
ALPN
| $28.9M | 1.17% |
933,103
| – | – |
|
27
McKesson
MCK
$98.5B
| $28.5M | 1.16% |
144,646
-41,000
| -22% | -$7.74M |
|
|
GHDX
28
DELISTED
Genomic Health, Inc.
GHDX
| $28.5M | 1.15% |
809,432
-284,084
| -26% | -$7.61M |
|
29
Pacira BioSciences
PCRX
$1.01B
| $28.5M | 1.15% |
371,000
-331,485
| -47% | -$18.8M |
|
|
FPRX
30
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $28.2M | 1.14% |
+680,000
| New | +$22.8M |
|
31
Zevra Therapeutics
ZVRA
$755M
| $28.2M | 1.14% |
88,781
| – | – |
|
|
SRRA
32
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $26.9M | 1.09% |
44,781
+11,071
| +33% | +$7.49M |
|
|
RLYP
33
DELISTED
RELYPSA INC COM
RLYP
| $25.5M | 1.03% |
900,281
-200,719
| -18% | -$4.32M |
|
|
GWPH
34
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $21.5M | 0.87% |
310,122
-81,000
| -21% | -$6.6M |
|
35
CytomX Therapeutics
CTMX
$788M
| $19.7M | 0.8% |
+946,022
| New | +$15M |
|
|
AERI
36
DELISTED
Aerie Pharmaceuticals
AERI
| $19.7M | 0.8% |
807,875
| – | – |
|
37
Protara Therapeutics
TARA
$230M
| $19.6M | 0.8% |
31,634
| – | – |
|
|
RAD
38
DELISTED
Rite Aid Corporation
RAD
| $19.5M | 0.79% |
124,639
-86,501
| -41% | -$12.8M |
|
39
Regenxbio
RGNX
$534M
| $19.4M | 0.79% |
1,169,042
-167,500
| -13% | -$3.32M |
|
40
Xencor
XNCR
$1.3B
| $18.4M | 0.74% |
1,256,612
-530,388
| -30% | -$7.13M |
|
41
Pacific Biosciences
PACB
$447M
| $18.2M | 0.74% |
1,388,000
-797,771
| -36% | -$7.16M |
|
|
ACHN
42
DELISTED
Achillion Pharmaceuticals
ACHN
| $18M | 0.73% |
1,667,000
| – | – |
|
43
Axogen
AXGN
$2.12B
| $16.9M | 0.69% |
3,381,439
| – | – |
|
|
DBVT
44
DBV Technologies
DBVT
$870M
| $16.8M | 0.68% |
46,187
| – | – |
|
|
AKTX
45
Akari Therapeutics
AKTX
$19.3M
| $16.7M | 0.68% |
1,438
| – | – |
|
46
Centene
CNC
$32.8B
| $16.1M | 0.65% |
+488,000
| New | +$14.5M |
|
47
MacroGenics
MGNX
$285M
| $16M | 0.65% |
517,920
-39,080
| -7% | -$1.19M |
|
|
CSII
48
DELISTED
Cardiovascular Systems, Inc.
CSII
| $15.6M | 0.63% |
+1,035,000
| New | +$15.4M |
|
|
GI
49
DELISTED
EndoChoice Holdings, Inc.
GI
| $15.2M | 0.62% |
1,823,309
+25,600
| +1% | +$246K |
|
|
ALIM
50
DELISTED
Alimera Sciences
ALIM
| $14.2M | 0.58% |
391,868
+97,163
| +33% | +$4.22M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q4 2015 Portfolio in Review
As of Q4 2015, Deerfield Management held 147 positions worth $2.47B, down 4.6% from $2.59B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Deerfield Management withdrew a net $497M in Q4 2015, closing 38 positions and reducing 28 holdings. Its most notable exit was bluebird bio, an estimated $41.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 69% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in Five Prime Therapeutics, Inc. worth $28.2M.
- Deerfield Management's largest Q4 2015 buy was Five Prime Therapeutics, Inc.: 680,000 shares worth $28.2M.
- Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015, an estimated $70.1M increase.
- Deerfield Management's biggest Q4 2015 reduction was NxStage Medical Inc., cutting an estimated $32.2M.
- Deerfield Management fully exited bluebird bio in Q4 2015, selling an estimated $41.3M.
- Deerfield Management's ten largest holdings make up 35% of its $2.47B portfolio in Q4 2015.
- Deerfield Management opened 13 new positions and closed 38 in Q4 2015.
- Deerfield Management's portfolio value fell 4.6% quarter-over-quarter to $2.47B.
Based on Deerfield Management's 13F filing for Q4 2015, filed 16 Feb 2016.